雜志介紹

Clinical Cancer Research雜志介紹

《Clinical Cancer Research》是一本以English為主的未開放獲取國際優(yōu)秀期刊，中文名稱臨床癌癥研究，本刊主要出版、報道醫(yī)學(xué)-ONCOLOGY領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進展，探討行業(yè)發(fā)展的思路和方法，以促進學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動作用，也得到了本專業(yè)人員的廣泛認可。該刊最新影響因子為10，最新CiteScore 指數(shù)為20.1。

本刊近期中國學(xué)者發(fā)表的論文主要有：

• Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy

  Author: Chen, Wei; Shi, Hui; Liu, Zhuojun; Yang, Fan; Liu, Jia; Zhang, Leqiang; Wu, Yajin; Xia, Yuanshi; Ou, Yuxuan; Li, Ruiting; Zhang, Ting; Zhang, Jiecheng; Ke, Xiaoyan; Hu, Kai; Yu, Jian

• Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies

  Author: Zhai, Yifan; Tang, Qiuqiong; Fang, Douglas D.; Deng, Jing; Zhang, Kaixiang; Wang, Qixin; Yin, Yan; Fu, Chengcheng; Xue, Sheng -Li; Li, Na; Zhou, Feng; Yang, Dajun

• Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer

  Author: Peng, Ke; Zhang, Feifei; Wang, Yichen; Sahgal, Pranshu; Li, Tianxia; Zhou, Jin; Liang, Xiaoyan; Zhang, Yanxi; Sethi, Nilay; Liu, Tianshu; Zhang, Haisheng; Bass, Adam J.

• Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes

  Author: Bai, Jiwei; Shi, Jianxin; Zhang, Yazhuo; Li, Chuzhong; Xiong, Yujia; Koka, Hela; Wang, Difei; Zhang, Tongwu; Song, Lei; Luo, Wen; Zhu, Bin; Hicks, Belynda; Hutchinson, Amy; Kirk, Erin; Troester, Melissa A.; Li, Mingxuan; Shen, Yutao; Ma, Tianshun; Wang, Junmei; Liu, Xing; Wang, Shuai; Gui, Songbai; McMaster, Mary L.; Chanock, Stephen J.; Parry, Dilys M.; Goldstein, Alisa M.; Yang, Xiaohong R.

英文介紹

Clinical Cancer Research雜志英文介紹

Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment. The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease.

Specific areas of interest include clinical and translational research in targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; novel applications of bioinformatics and biostatistics; immunotherapy and clinical immunology; gene therapy; radiobiology and radiation oncology; large-scale molecular characterization of human tumors; diagnostic biomarkers; innovative imaging and other novel methods with potential applicability to clinical investigation; clinical genetics; and detection of minimal disease.